Bristol-Myers Squibb stops Phase III trial of apixaban on "clear evidence" of efficacy
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has halted the Phase III AVERROES trial of its apixaban in vitamin K antagonist intolerant patients with atrial fibrillation (AF), citing interim data that showed the drug reduced stroke and systemic embolism compared with aspirin. The company, which is developing the drug with Pfizer, added the drug had a promising safety profile in the trial.